Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375492 | 0.83 | ALDH1A1 (0.41) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| SCHEMBL27191984 | 0.82 | MKNK1 (0.44) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL15367005 | 0.82 | ALDH1A1 (0.39) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| SCHEMBL29951442 | 0.82 | DGAT1 (0.56) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| SCHEMBL2930047 | 0.82 | TTR (0.53) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| SCHEMBL290252 | 0.82 | DGAT1 (0.56) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| SCHEMBL790041 | 0.82 | DGAT1 (0.43) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| SCHEMBL1787715 | 0.82 | ALDH1A1 (0.47) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| SCHEMBL30016565 | 0.77 | MKNK1 (0.48) | ENPP2KDM4ECA2ALDH1A1CA1 | |
| SCHEMBL918043 | 0.76 | ALDH1A1 (0.44) | ENPP2KDM4ECA2ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ENPP2 1920/4885KDM4E 2606/4885CA2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.